Literature DB >> 23303882

In the coming year we should abandon interferons and glatiramer acetate as first line therapy for MS: commentary.

Michael Hutchinson.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23303882     DOI: 10.1177/1352458512470507

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


× No keyword cloud information.
  2 in total

Review 1.  Cost-Effectiveness Modeling in Multiple Sclerosis: Playing Around with Non-Healthcare Costs?

Authors:  Livio Garattini; Francesca Ghislandi; Milene Rangel Da Costa
Journal:  Pharmacoeconomics       Date:  2015-12       Impact factor: 4.981

2.  Treatment satisfaction in multiple sclerosis.

Authors:  Bonnie I Glanz; Alexander Musallam; David J Rintell; Tanuja Chitnis; Howard L Weiner; Brian C Healy
Journal:  Int J MS Care       Date:  2014
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.